Todays Report: Today, CVS Health Corporation (CVS) Downgraded by Vetr Inc.

Today, CVS Health Corporation (CVS) Downgraded by Vetr Inc.

CVS Health Corporation (NYSE:CVS) was downgraded by equities research analysts at Vetr from a “strong-buy” rating to a “hold” rating in a research note issued on Thursday. They currently have a $87.73 price target on the pharmacy operator’s stock. Vetr‘s price objective points to a potential upside of 1.77% from the stock’s current price.

Several other equities research analysts have also recently issued reports on the stock. Credit Suisse Group AG restated an “outperform” rating and set a $110.00 price objective (down from $115.00) on shares of CVS Health Corporation in a research report on Tuesday. Robert W. Baird cut their price objective on shares of CVS Health Corporation from $114.00 to $104.00 and set an “outperform” rating for the company in a research report on Monday. Leerink Swann restated an “outperform” rating and set a $105.00 price objective (down from $110.00) on shares of CVS Health Corporation in a research report on Sunday. Mizuho restated a “buy” rating and set a $111.00 price objective on shares of CVS Health Corporation in a research report on Friday, September 30th. Finally, Morgan Stanley restated a “hold” rating and set a $104.00 price objective on shares of CVS Health Corporation in a research report on Monday, September 12th. Six equities research analysts have rated the stock with a hold rating, seventeen have given a buy rating and one has issued a strong buy rating to the stock. CVS Health Corporation currently has a consensus rating of “Buy” and a consensus price target of $112.11.

Shares of CVS Health Corporation (NYSE:CVS) opened at 86.20 on Thursday. The stock has a 50 day moving average of $92.04 and a 200 day moving average of $97.10. CVS Health Corporation has a 12-month low of $85.89 and a 12-month high of $106.67. The company has a market cap of $91.91 billion, a price-to-earnings ratio of 19.83 and a beta of 0.83.

10/06/cvs-health-corporation-cvs-downgraded-by-vetr-inc.html

CVS Health Corporation (NYSE:CVS) last released its quarterly earnings data on Tuesday, August 2nd. The pharmacy operator reported $1.32 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $1.30 by $0.02. CVS Health Corporation had a net margin of 2.88% and a return on equity of 15.86%. The firm earned $43.70 billion during the quarter, compared to analysts’ expectations of $44.28 billion. During the same period last year, the business earned $1.19 earnings per share. CVS Health Corporation’s revenue was up 17.6% compared to the same quarter last year. Analysts forecast that CVS Health Corporation will post $5.86 earnings per share for the current year.

The firm also recently announced a quarterly dividend, which will be paid on Thursday, November 3rd. Stockholders of record on Monday, October 24th will be issued a $0.425 dividend. The ex-dividend date is Thursday, October 20th. This represents a $1.70 dividend on an annualized basis and a dividend yield of 1.97%. CVS Health Corporation’s payout ratio is 39.08%.

Institutional investors have recently made changes to their positions in the stock. Acrospire Investment Management LLC boosted its position in shares of CVS Health Corporation by 542.2% in the second quarter. Acrospire Investment Management LLC now owns 1,066 shares of the pharmacy operator’s stock valued at $102,000 after buying an additional 900 shares in the last quarter. MU Investments Co. Ltd. boosted its position in shares of CVS Health Corporation by 62.0% in the second quarter. MU Investments Co. Ltd. now owns 1,150 shares of the pharmacy operator’s stock valued at $109,000 after buying an additional 440 shares in the last quarter. Pinkerton Retirement Specialists LLC boosted its position in shares of CVS Health Corporation by 3,475.0% in the second quarter. Pinkerton Retirement Specialists LLC now owns 1,144 shares of the pharmacy operator’s stock valued at $110,000 after buying an additional 1,112 shares in the last quarter. D Orazio & Associates Inc. boosted its position in shares of CVS Health Corporation by 9.4% in the second quarter. D Orazio & Associates Inc. now owns 1,160 shares of the pharmacy operator’s stock valued at $111,000 after buying an additional 100 shares in the last quarter. Finally, Cantab Capital Partners LLP boosted its position in shares of CVS Health Corporation by 355.4% in the second quarter. Cantab Capital Partners LLP now owns 1,184 shares of the pharmacy operator’s stock valued at $113,000 after buying an additional 924 shares in the last quarter. 80.96% of the stock is currently owned by institutional investors.

About CVS Health Corporation

CVS Health Corporation, together with its subsidiaries (CVS Health), is a pharmacy company. The Company operates through three business segments: Pharmacy Services, Retail/LTC and Corporate. The Company offers a range of products and services, such as advising patients on their medications at its CVS Pharmacy locations, introducing programs to help control costs for its clients at CVS Caremark, how care is delivered to its patients with conditions through CVS Specialty, pharmacy care for the senior community through Omnicare.

Related posts

Leave a Comment